Conventional DCs (CD45+CD11c+MHC‐II+), especially CLEC9A+ type 1 conventional DCs (cDC1) subset, play a critical role in tumor antigens trafficking and antitumor T cell priming, which is closely related to the efficacy of tumor immunotherapies.[22] The treatment with FK‐13 promoted the bone marrow cells differentiation into conventional DCs, CLEC9A+ cDC1 subpopulation and enhanced the expression levels of costimulatory molecules on DCs, including CD40, CD80, CD86 (Figure 1D–H), indicating the activation of DCs. Here, CD40 is linked to neoplasm.